| Authors: |
Wellinger LC; Roche Pharma Research and Early Development, Oncology Discovery, Roche Innovation Center Basel, Basel, Switzerland., Hogg SJ; Translational Hematology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia., Newman DM; Translational Hematology Program, Peter MacCallum Cancer Centre, Melbourne, Australia., Friess T; Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany., Geiss D; Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany., Michie J; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia., Ramsbottom KM; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia., Bacac M; Roche Pharma Research and Early Development, Oncology Discovery, Roche Innovation Center Zurich, Schlieren, Switzerland., Fauti T; Roche Pharma Research and Early Development, Oncology Discovery, Roche Innovation Center Zurich, Schlieren, Switzerland., Marbach D; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland., Jarassier L; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland., Thienger P; Department for BioMedical Research, University of Bern, Bern, Switzerland., Paehler A; Roche Pharma Research and Early Development, Oncology Discovery, Roche Innovation Center Basel, Basel, Switzerland., Cluse LA; Translational Hematology Program, Peter MacCallum Cancer Centre, Melbourne, Australia., Kearney CJ; Translational Hematology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia., Vervoort SJ; Translational Hematology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia., Trapani JA; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia., Oliaro J; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia., Shortt J; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.; Monash Haematology, Monash Health, Clayton, Australia.; School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia., Ruefli-Brasse A; Pfizer, South San Francisco, California., Rohle D; Roche Pharma Research and Early Development, Oncology Discovery, Roche Innovation Center Basel, Basel, Switzerland. drohle@ridgelinediscovery.com ricky.johnstone@petermac.org., Johnstone RW; Translational Hematology Program, Peter MacCallum Cancer Centre, Melbourne, Australia. drohle@ridgelinediscovery.com ricky.johnstone@petermac.org.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia. |
